Alligator Bioscience AB (ATORX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alligator Bioscience AB (ATORX) has a cash flow conversion efficiency ratio of -3.791x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-26.00 Million ≈ $-2.80 Million USD) by net assets (Skr6.86 Million ≈ $738.14K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Alligator Bioscience AB - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Alligator Bioscience AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Alligator Bioscience AB total liabilities for a breakdown of total debt and financial obligations.
Alligator Bioscience AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alligator Bioscience AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Senior PLC
LSE:SNR
|
0.147x |
|
Cloudastructure, Inc. Class A Common Stock
NASDAQ:CSAI
|
-0.141x |
|
Toppoint Holdings Inc.
NYSE MKT:TOPP
|
-0.049x |
|
Anugerah Kagum Karya Utama Tbk PT
JK:AKKU
|
0.000x |
|
Tarmat Limited
NSE:TARMAT
|
0.016x |
|
Barramundi Group Ltd
OL:BARRA
|
0.044x |
|
Goodfood Market Corp
TO:FOOD
|
-0.013x |
|
Clal Biotechnology Industries Ltd
TA:CBI
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Alligator Bioscience AB (2011–2025)
The table below shows the annual cash flow conversion efficiency of Alligator Bioscience AB from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Alligator Bioscience AB (ATORX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr6.86 Million ≈ $738.14K |
Skr-155.99 Million ≈ $-16.79 Million |
-22.742x | -1498.03% |
| 2024-12-31 | Skr-130.59 Million ≈ $-14.05 Million |
Skr-212.43 Million ≈ $-22.86 Million |
1.627x | +110.19% |
| 2023-12-31 | Skr11.86 Million ≈ $1.28 Million |
Skr-189.28 Million ≈ $-20.37 Million |
-15.967x | -723.75% |
| 2022-12-31 | Skr89.05 Million ≈ $9.58 Million |
Skr-172.61 Million ≈ $-18.58 Million |
-1.938x | -330.70% |
| 2021-12-31 | Skr282.27 Million ≈ $30.38 Million |
Skr-127.03 Million ≈ $-13.67 Million |
-0.450x | +63.31% |
| 2020-12-31 | Skr115.24 Million ≈ $12.40 Million |
Skr-141.35 Million ≈ $-15.21 Million |
-1.227x | -77.16% |
| 2019-12-31 | Skr258.50 Million ≈ $27.82 Million |
Skr-178.96 Million ≈ $-19.26 Million |
-0.692x | -211.41% |
| 2018-12-31 | Skr468.31 Million ≈ $50.40 Million |
Skr-104.11 Million ≈ $-11.20 Million |
-0.222x | -37.90% |
| 2017-12-31 | Skr617.96 Million ≈ $66.50 Million |
Skr-99.63 Million ≈ $-10.72 Million |
-0.161x | -189.86% |
| 2016-12-31 | Skr676.18 Million ≈ $72.77 Million |
Skr-37.61 Million ≈ $-4.05 Million |
-0.056x | -110.78% |
| 2015-12-31 | Skr396.97 Million ≈ $42.72 Million |
Skr204.89 Million ≈ $22.05 Million |
0.516x | +156.37% |
| 2014-12-31 | Skr68.52 Million ≈ $7.37 Million |
Skr-62.74 Million ≈ $-6.75 Million |
-0.916x | +43.36% |
| 2011-12-31 | Skr21.51 Million ≈ $2.31 Million |
Skr-34.77 Million ≈ $-3.74 Million |
-1.617x | -- |
About Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, develo… Read more